– CNBC
ASLAN Pharmaceuticals Announces First Patient Screened In Study Of Eblasakimab In Dupilumab Experienced Atopic Dermatitis Patients
The TRials with EblasaKimab in Dupilumab eXperienced atopic dermatitis patients (TREK-DX) study will evaluate eblasakimab in a patient population with few safe treatment options
The study will enroll 75